Join BioNJ in our efforts to protect Patients and medical innovation from ICER.
BioNJ has created the following digital advocacy toolkit of social media posts, shareable graphics, video, and email content to empower you and your organization to lend your voice on the importance of protecting medical innovation on behalf of Patients. Please consider customizing, distributing, and sharing the following resources across your professional and personal digital channels and with partners to protect medical innovation in New Jersey and promote Patient advocacy.
Social Media Content: Protecting Medical Innovation in New Jersey NOTE: Posts are customized to fit Twitter character limits. Social Media Graphics: Protecting Medical Innovation in New Jersey. Social Media Content: Video – The Value of Medical Innovation NOTE: Posts are customized to fit Twitter character limits. Social Media Content: Video – Protect Patients & Innovation from the Threat of ICER NOTE: Posts are customized to fit Twitter character limits. Social Media Content: BioNJ Infographic – Protecting Medical Innovation in New Jersey Click to Download the BioNJ Infographic – Protecting Medical Innovation in New Jersey From ICER Social Media Content: BioNJ Grassroots Email Advocacy Program NOTE: Posts are customized to fit Twitter character limits. Social Media Graphics: Protecting Medical Innovation in New Jersey Email Newsletter Template: Protecting Medical Innovation in New Jersey SUBJECT LINE: What Does ICER Mean for Patients? Dear Friend, As you may know, the Institute for Clinical and Economic Review (ICER) threatens to have a big impact on Patients here in New Jersey and the medical innovation ecosystem that Patients around the country rely on to produce life-changing treatments and cures. The ICER “Value Assessment” Model Patients and innovation could be under attack if policymakers in New Jersey consider adopting ICER’s controversial “value assessment” reports to determine access to care. ICER uses a flawed method to determine the value of drugs, based on an arbitrary evaluation of the value of one year of “perfect health.” The “Quality Adjusted Life Years (QALY)” Method ICER’s “value assessment” reports on new drugs analyze how well a drug works, its economic value, and other elements of value. To do this, ICER uses the “Quality Adjusted Life Years (QALY)” technique to determine the cost-effectiveness of drugs, assigning a random evaluation of the monetary worth of one year of “perfect health.” ICER Ignores the Patient Voice In its reviews, ICER ignores individual Patient preferences, and the QALY disregards individual circumstances such as age, condition, or unique Patient needs. The QALY methodology and similar approaches to drug value assessment may also be discriminatory, as it places a lower value on the lives of the disabled and elderly. If ICER principles are adopted in New Jersey, their reviews could be devastating for medical innovation and have unintended consequences for Patients. Because Patients Can’t Wait®, any solution to control health care costs in New Jersey must promote innovation, incorporate the unique needs of Patients, and ensure access to care. Join BioNJ in their efforts to protect medical innovation and access to life-changing treatments for New Jerseyans and all Americans. Sign up and they will send you email opportunities to take action online and in your community. Learn more at BioNJ.org/Protect-Medical-Innovation.
Click on the thumbnail below. Right click and select “save as picture” to save locally to your computer.
Click on the thumbnail below. Right click and select “save as picture” to save locally to your computer. 